Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: heart attack

FDA Rejects Novartis Bid to Repurpose Inflammation Drug for Heart Attacks

John Miller  |  October 22, 2018

ZURICH (Reuters)—The U.S. Food and Drug Administration (FDA) has rejected Novartis’s bid to repurpose a drug now approved for rare inflammatory diseases to be used in a group of heart attack survivors, according to the Swiss drugmaker. The company received an FDA letter turning down its bid to make canakinumab a targeted therapy for those…

Filed under:Drug Updates Tagged with:canakinumabcardiovascularFamilial Mediterranean feverFDAheartNovartisU.S. Food and Drug Administration (FDA)

Drug Safety: Fasinumab Evaluated in Clinical Trials, Plus Celecoxib May Not Pose Increased Heart Attack or Stroke Risk

Michele B. Kaufman, PharmD, BCGP  |  May 15, 2018

After an independent review, ongoing clinical trials investigating the safety of fasinumab for treating hip or knee OA will discontinue the use of higher fasinumab doses…

Filed under:Drug Updates Tagged with:celecoxib (Elyxyb)Drug SafetyfasinumabFDAhipkneeKnee Osteoarthritis (OA)Nonsteroidal anti-inflammatory drugs (NSAIDs)PainPain ManagementU.S. Food and Drug Administration (FDA)

Family History Biggest Predictor of Heart Attacks in People with Psoriasis

Lisa Rapaport  |  July 2, 2016

(Reuters Health)—People with psoriasis, a chronic inflammatory disease, are more likely to have heart attacks and strokes when they have a family history of cardiovascular problems, a Danish study suggests. Psoriasis wasn’t associated with higher risk of heart attacks or strokes when people with the skin condition didn’t have a family history of cardiovascular disease,…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:cardiovascularheartPsoriasis

Coronary Microvascular Dysfunction May Predict Heart Disease in Rheumatoid Arthritis

Kurt Ullman  |  December 14, 2020

Cardiovascular disease (CVD) is a leading cause of death in patients with rheumatoid arthritis (RA). Patients with RA have a 1.5 times increased risk for heart attack compared with the general population. Although the treatment of RA has advanced significantly, the ability to prevent cardiovascular events hasn’t followed. A study in Arthritis Care & Research…

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:Cardiovascular diseasecoronary microvascular disease

Study Finds Newer Gout Drug Poses Risk to Heart Patients

Gene Emery  |  March 12, 2018

(Reuters Health)—Gout sufferers with major pre-existing heart disease face a higher risk of death if they are treated with the drug febuxostat, a large long-term study has concluded. The risk of death from cardiovascular disease was 34% higher with febuxostat than with allopurinol. When researchers considered deaths from any cause, the risk was 22% higher…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:AllopurinolCardiovascular diseaseFebuxostatGoutHeart Diseasestroke

English Hospitals Divert Ambulances After Ransomware Cyber Attack

Costas Pitas & Alistair Smout  |  May 12, 2017

LONDON (Reuters)—Hospitals and doctors’ surgeries across England were forced to turn away patients and cancel appointments on Friday after a nationwide ‘ransomware’ cyber attack crippled some computer systems in the state-run health service. The U.K. National Health Service (NHS) said 16 organizations had been affected by the cyber attack but said it had not been…

Filed under:FacilityPractice Support Tagged with:cyber securityhospitalNational Health Service (NHS)U.K.

Psoriatic Arthritis Linked to Increased Heart Disease Risk

Carolyn Crist  |  January 17, 2017

(Reuters Health)—Arthritis that accompanies the skin condition psoriasis may also come with a higher risk of heart problems, according to a Hong Kong study. In particular, patients with psoriatic arthritis may have a three- to four-fold higher prevalence of coronary atherosclerosis. Clinicians need to identify patients with high cardiovascular (CV) risk so they can provide…

Filed under:ConditionsPsoriatic Arthritis Tagged with:coronary plaqueHeart DiseaseNational Psoriasis FoundationPsoriasisPsoriatic Arthritis

Opinion: Paris Terrorist Attacks Shouldn’t Keep Rheumatologists from Attending Next ACR/ARHP Annual Meeting

Katarzyna Gilek-Seibert, MD  |  March 15, 2016

Friday, Nov. 13, 2015. The day Paris came under attack—again. What Came Before Not even 48 hours before that day, I had said my last goodbyes: the teary eyes, the final hugs, promising to stay in touch and, perhaps, see my friends next year at the ACR/ARHP Annual Meeting. Snap and share another photo. I…

Filed under:Professional Topics Tagged with:ACR/ARHP Annual Meetingrheumatologistshooting

Heart Disease: Major Risk Factor for Many Rheumatology Patients

Vanessa Caceres  |  October 14, 2015

Rheumatic diseases, such as rheuma­toid arthritis (RA), systemic lupus erythematosus (SLE) and vasculitis, can affect the body in many ways, but perhaps the most serious is the increased risk of heart disease for many patients. As the risk of atherosclerosis in autoimmune disease patients gains increased attention, rheumatologists and cardiologists are collaborating more often to…

Filed under:ConditionsRheumatoid Arthritis Tagged with:cardiologistsClinicalHeart Diseasepatient careRARheumatoid arthritisrheumatologistrisk

NSAIDs: The Heart of the Controversy

Kurt Ullman  |  June 1, 2007

Rheumatologists on the AHA statement and how to balance NSAID risks and benefits

Filed under:AnalgesicsDrug Updates Tagged with:AC&RdosageNonsteroidal anti-inflammatory drugs (NSAIDs)patient carerheumatologistSafetyside effect

  • 1
  • 2
  • 3
  • …
  • 16
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences